Acura OTC Stock Insiders


USD 0.01  0.00  0.00%   

Acura Pharma employes about 12 people. The company is managed by 10 executives with total tenure of roughly 162 years, averaging almost 16.0 years of service per executive having 1.2 employees per reported executive. Discussion of Acura Pharma management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Acura Pharma Cmn future performance.
Please continue to Trending Equities.
  Robert Jones  CEO
CEO and President and Director
  James Emigh  President
Vice President - Corporate Development

Acura Pharma Management Team Effectiveness

Acura Pharma Cmn has return on total asset (ROA) of (38.42) % which means that it has lost $38.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.85 %, meaning that it created $0.85 on every $100 dollars invested by stockholders. Acura Pharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Acura Pharma Workforce Comparison

Acura Pharma Cmn is number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 32,012. Acura Pharma adds roughly 12.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.

Acura Pharma Profit Margins

The company has Profit Margin (PM) of (51.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (49.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.49.

Acura Pharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acura Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acura Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Acura Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Acura Pharma Cmn Benchmark Summation

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Indexes of lowest and highest values over a specified period line shows minimum and maximum index of Acura Pharma Cmn price series.

Acura Pharma Notable Stakeholders

An Acura Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Acura Pharma often face trade-offs trying to please all of them. Acura Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Acura Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Jones - CEO and President and DirectorProfile
James Emigh - Vice President - Corporate DevelopmentProfile
Peter Clemens - CFO, Principal Accounting Officer, Sr. VP and SecretaryProfile
George Ross - Independent DirectorProfile
Bruce Wesson - Independent DirectorProfile
Immanuel Thangaraj - Independent DirectorProfile
William Skelly - Independent DirectorProfile
Albert Brzeczko - VP of Technical AffairsProfile
Robert Seiser - VP, Treasurer and Corporate ControllerProfile
Bradley Rivet - VP of MarketingProfile

About Acura Pharma Management Performance

The success or failure of an entity such as Acura Pharma Cmn often depends on how effective the management is. Acura Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Acura management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Acura management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 12 people.
The data published in Acura Pharma's official financial statements usually reflect Acura Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Acura Pharma Cmn. For example, before you start analyzing numbers published by Acura accountants, it's critical to develop an understanding of what Acura Pharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Acura Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Acura Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Acura Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Acura Pharma Cmn. Please utilize our Beneish M Score to check the likelihood of Acura Pharma's management to manipulate its earnings.

Acura Pharma Workforce Analysis

Traditionally, organizations such as Acura Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Acura Pharma within its industry.

Acura Pharma Manpower Efficiency

Return on Acura Pharma Manpower

Revenue Per Employee187.5 K
Revenue Per Executive225 K
Net Loss Per Employee95.8 K
Net Loss Per Executive115 K
Working Capital Per Employee907.6 K
Working Capital Per Executive1.1 M
Please continue to Trending Equities. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for analysis

When running Acura Pharma Cmn price analysis, check to measure Acura Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acura Pharma is operating at the current time. Most of Acura Pharma's value examination focuses on studying past and present price action to predict the probability of Acura Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acura Pharma's price. Additionally, you may evaluate how the addition of Acura Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Acura Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acura Pharma. If investors know Acura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acura Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Acura Pharma Cmn is measured differently than its book value, which is the value of Acura that is recorded on the company's balance sheet. Investors also form their own opinion of Acura Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acura Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acura Pharma's market value can be influenced by many factors that don't directly affect Acura Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acura Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Acura Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acura Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.